11 employees
OrsoBio develops therapies to treat severe metabolic disorders, including type 2 diabetes, and other conditions.
2021
$2.3M
from 1 investors over 1 rounds
OrsoBio raised $2.3M on November 2, 2022
Investors: NIDDK, NIH